---
title: "Zevra Therapeutics Chief Legal & Compliance Rahsaan Thompson sells 42,666 shares for $474,781.44"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296143510.md"
description: "Zevra Therapeutics Chief Legal & Compliance Officer Rahsaan Thompson sold 42,666 common shares on August 14, 2026, at a weighted average price of $11.13 per share, totaling $474,781.44. Following the transaction, his directly held stake decreased to 37,569 shares."
datetime: "2026-08-17T20:33:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296143510.md)
  - [en](https://longbridge.com/en/news/296143510.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296143510.md)
generator: "portal-rs"
---

# Zevra Therapeutics Chief Legal & Compliance Rahsaan Thompson sells 42,666 shares for $474,781.44

-   Rahsaan Thompson, Chief Legal & Compliance Officer at Zevra Therapeutics, sold 42,666 common shares on Aug. 14, 2026. \* Weighted average sale price USD 11.13 per share. \* Directly held stake fell to 37,569 common shares following the sale. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zevra Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001434647-26-000073), on August 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ZVRA.US](https://longbridge.com/en/quote/ZVRA.US.md)

## Related News & Research

- [Zevra Therapeutics Chief Legal & Compliance Rahsaan Thompson sells 34,557 shares for $438,216.86](https://longbridge.com/en/news/290604444.md)
- [Zevra Therapeutics (ZVRA) Following EMA Setback Is The Sell Off A Valuation Gap](https://longbridge.com/en/news/293819040.md)
- [TAESA energizes Garabi 2 converter, adding about R$ 24.2 million to Saíra annual revenue entitlement](https://longbridge.com/en/news/296538089.md)
- [Zevra publishes four-year real-world U.S. early access data on MIPLYFFA in Niemann-Pick disease type C](https://longbridge.com/en/news/294685995.md)
- [Zevra: Buy Rating Reaffirmed on Strong MIPLYFFA Momentum and U.S. NPC Opportunity; Price Target Maintained at $35](https://longbridge.com/en/news/295278479.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**